Bli medlem
Bli medlem

Du är här

2016-12-16

Acarix AB: Nasdaq Stockholm AB has approved Acarix AB (publ) as issuer of shares on Nasdaq First North Premier. First day of trading will commence on December 1

Press Release December 16, 2016

Nasdaq Stockholm AB has approved Acarix AB (publ) as issuer of shares on
Nasdaq First North Premier. First day of trading will commence on December
19, 2016.

Acarix AB (publ) ("Acarix" or the "Company") has today been approved by Nasdaq
Stockholm AB as issuer of shares on Nasdaq First North Premier ("Nasdaq First
North Premier") in Stockholm. The first day of trading will commence on
December 19, 2016.

Acarix is a Swedish/Danish commercial stage medical device company,
specialised in non-invasive, non-radiative acoustic rule-out of Coronary
Artery Disease (CAD). Prior to the first day of trading on Nasdaq First North
Premier, the company raised SEK 140 million before transaction costs in a
well-oversubscribed share issue, which added around 1,200 new shareholders to
the Company's register.
Trading Information

Short name (ticker) on Nasdaq First North Premier: ACARIX
ISIN-code: SE0009268717

Advisors

Vator Securities is the financial advisor and Baker McKenzie is the legal
advisor to the Company in connection with the initial public offering on
Nasdaq First North Premier. Wildeco is the Certified Advisor to the Company.

For more information, please contact:

Søren Rysholt Christiansen, CEO, Acarix
E-mail: dksrc@acarix.com
Phone: +45 2777 1112

Notes to editors:

Acarix , CADScor®System and cardiac sound measurement

Acarix was established in 2009 as a spinout company from Coloplast A/S. Since
2010 key investors Seed Capital (DK) and Sunstone Life Science Ventures (DK)
have financed the development of the company and supported it towards market
introduction. While some founders remain in the company, Acarix has attracted
a highly experienced management team who have held senior positions in
international medical device companies - CEO Søren Rysholt Christiansen with
ELOS Medtech, GN ReSound and Cook Medical.

Acarix' CADScor®System is based on pioneering research at Aalborg University.
It has long been known that both cardiac contraction movement and turbulent
flow can generate sound. Contraction related sounds are in lower frequency,
whereas turbulent sounds in the streaming blood caused by partial obstruction
(stenosis) in the coronary arteries are of higher frequencies. The detection
of these murmurs is delicate, since the energy of the murmurs is very weak.
Detecting and recording the coronary murmurs requires not only an advanced
sensor but also means for proper attachment to the skin above the heart to
optimize the recorded signal and to avoid external noise.
The Acarix CADScor®System has been designed to be an all-in-one system in the
sense that the heart signal will be recorded, processed and displayed as a
patient specific score, the CAD-score, on the device screen.

The CADScor®System contains the necessary electronics to instruct
professionals during use and guide the patient through the recording periods.
The system also contains a docking station for daily qualification of the
sensor. Further the system integrates with an adhesive patch for locking the
CADScor®sensor to a fixed position above the heart during the recording.

The software embedded in The Acarix CADScor®System ensures that adequate
recording conditions are controlled at every examination, whether performing
your examinations in a quiet clinical settings or at busy GP clinics, at high
altitudes (>95% coverage) or on the move.

The CADScor®System is CE Marked (by TÜV in 2015) and due for commercial launch
in 2017.

See more atwww.acarix.com.

Important information

This announcement is not and does not form a part of any offer for sale of
securities. Copies of this announcement are not being made and may not be
distributed or sent into the United States, Australia, Canada, Hong Kong,
Japan, South Africa or any other jurisdiction in which such distribution
would be unlawful or would require registration or other measures. The
securities referred to in this announcement have not been and will not be
registered under the U.S. Securities Act of 1933, as amended (the "Securities
Act"), and accordingly may not be offered or sold in the United States absent
registration or an exemption from the registration requirements of the
Securities Act and in accordance with applicable U.S. state securities laws.
The company does not intend to register any offering in the United States or
to conduct a public offering of securities in the United States.

The offering of securities referred to in this announcement has been made by
means of a prospectus. This announcement is not a prospectus for the purposes
of Directive 2003/71/EC (together with any applicable implementing measures
in any Member State, the "Prospectus Directive"). Investors should not invest
in any securities referred to in this announcement except on the basis of
information contained in the aforementioned prospectus. In any EEA Member
State other than Sweden that has implemented the Prospectus Directive, this
communication is only addressed to and is only directed at qualified
investors in that Member State within the meaning of the Prospectus
Directive, i.e., only to investors who can receive the offer without an
approved prospectus in such EEA Member State.

This communication is only being distributed to and is only directed at
persons in the United Kingdom that are (i) investment professionals falling
within Article 19(5) of the Financial Services and Markets Act 2000
(Financial Promotion) Order 2005, as amended (the "Order") or (ii) high net
worth entities, and other persons to whom this announcement may lawfully be
communicated, falling within Article 49(2)(a) to (d) of the Order (all such
persons together being referred to as "Relevant Persons"). This communication
must not be acted on or relied on by persons who are not Relevant Persons.
Any investment or investment activity to which this communication relates is
available only to Relevant Persons and will be engaged in only with Relevant
Persons. Persons distributing this communication must satisfy themselves that
it is lawful to do so.

Matters discussed in this announcement may constitute forward-looking
statements. Forward-looking statements are statements that are not historical
facts and may be identified by words such as "believe," "expect,"
"anticipate," "intends," "estimate," "will," "may," "continue," "should" and
similar expressions. The forward-looking statements in this release are based
upon various assumptions, many of which are based, in turn, upon further
assumptions. Although the company believes that these assumptions were
reasonable when made, these assumptions are inherently subject to significant
known and unknown risks, uncertainties, contingencies and other important
factors that are difficult or impossible to predict and are beyond its
control. Such risks, uncertainties, contingencies and other important factors
could cause actual events to differ materially from the expectations
expressed or implied in this release by such forward- looking statements. The
information, opinions and forward-looking statements contained in this
announcement speak only as at its date, and are subject to change without
notice.

Acarix - Press Release 2016-12-16 (1)
http://hugin.info/173338/R/2065976/775584.pdf

---------------------------------------
This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Acarix AB via Globenewswire

Författare Hugin

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.